Capital Asset Advisory Services LLC Makes New $942,000 Investment in Boston Scientific Corporation $BSX

Capital Asset Advisory Services LLC bought a new position in Boston Scientific Corporation (NYSE:BSX) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 15,438 shares of the medical equipment provider’s stock, valued at approximately $942,000.

Several other hedge funds have also made changes to their positions in BSX. Essex Financial Services Inc. lifted its stake in Boston Scientific by 89.4% in the 1st quarter. Essex Financial Services Inc. now owns 4,859 shares of the medical equipment provider’s stock worth $305,000 after acquiring an additional 2,294 shares in the last quarter. CHICAGO TRUST Co NA lifted its position in shares of Boston Scientific by 10.1% in the first quarter. CHICAGO TRUST Co NA now owns 32,887 shares of the medical equipment provider’s stock worth $2,064,000 after purchasing an additional 3,009 shares in the last quarter. Deltec Asset Management LLC boosted its holdings in shares of Boston Scientific by 31.0% during the first quarter. Deltec Asset Management LLC now owns 55,400 shares of the medical equipment provider’s stock worth $3,476,000 after purchasing an additional 13,100 shares during the period. USS Investment Management Ltd grew its position in Boston Scientific by 4.6% during the first quarter. USS Investment Management Ltd now owns 269,031 shares of the medical equipment provider’s stock valued at $16,876,000 after purchasing an additional 11,950 shares in the last quarter. Finally, IFM Investors Pty Ltd grew its position in Boston Scientific by 2.5% during the first quarter. IFM Investors Pty Ltd now owns 332,339 shares of the medical equipment provider’s stock valued at $20,854,000 after purchasing an additional 8,151 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig purchased 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David C. Habiger acquired 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 9,800 shares of company stock worth $554,012 over the last 90 days. Insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

BSX has been the subject of a number of research analyst reports. BTIG Research reiterated a “buy” rating and issued a $65.00 target price on shares of Boston Scientific in a research report on Tuesday, June 16th. Citigroup cut their price objective on Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, May 28th. Zacks Research cut Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Truist Financial lowered their target price on Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a research note on Thursday, June 4th. Finally, Jefferies Financial Group dropped their target price on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $83.36.

Boston Scientific Trading Up 4.7%

Boston Scientific stock opened at $45.09 on Friday. Boston Scientific Corporation has a one year low of $42.25 and a one year high of $109.50. The company’s fifty day moving average price is $51.39 and its two-hundred day moving average price is $69.60. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company has a market capitalization of $67.01 billion, a price-to-earnings ratio of 18.86, a PEG ratio of 0.82 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the previous year, the firm earned $0.75 earnings per share. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.